Etteplan's Q2 fell short of our estimates due to continued low customer activity.
Redeye comments on Thunderful Group ahead of its Q2 results (due 21 August).
Redeye states that while the Q2 report held few positive surprises, all eyes are now (once again) on...
Redeye provides an update following Optomed’s Q2 report.
Paper EBITDA PLN 50m, below ABGSCe PLN 59m Group EBITDA miss driven by weaker on both paper and pulp...
Redeye briefly comments on Maximum Entertainment’s announcement that the chairman of the board has a...
- Solid Q2 report across the board, 1% better EBITA - More marketing campaigns in Q3 to boost the cu...
AcuCort (”AcuCort” eller ”Bolaget”) meddelade den 8 augusti år 2024 att Bolagets läkemedel Zeqmelit®...
Etteplan's Q2 results missed our estimates across the board.
Redeye continues to be positive to Bredband2 following a Q2 report in line with our estimates postin...
Redeye comments on Tessin’s Q2 results, which were in line with expectations.
Redeye notes that Q2 sales and EBIT were lower than anticipated.
CapMan's turnover in Q2 amounted to EUR 18.3m, above our estimates and consensus (EUR 16.
Redeye updates its view on Xspray following the Dasynoc CRL and the Q2 report.
Sales -1% vs. ABGSC, driving 7% adj. EBIT miss We see consensus estimates coming down 2-3% Conferenc...
Redeye comments on G5’s Q2-results which were slighlty lower than our forecasts while the company re...
Redeye states that Q2 2024 was solid, beating estimates across the board.
Ahead of Relais' Q2 report, due on 15 August, we make only minor underlying estimate revisions and i...
Redeye updates its estimates and valuation after reviewing Fantasma Games’ Q2 report, which came in ...
Obducat AB (publ) (”Obducat” eller ”Bolaget”) levererade ett starkt andra kvartal år 2024 trots utma...